Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

Myeloma

The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells

Abstract

Ethical and scientific concerns regarding the use of human fetal bones in the SCID-hu model of primary human myeloma prompted us to develop a novel system that uses rabbit bones implanted subcutaneously in unconditioned SCID mice. Immunohistochemical analysis of the implanted bone revealed that the majority of bone marrow (BM) microenvironment cells such as blood vessels, osteoclasts and osteoblasts were of rabbit origin. The implanted bones were directly injected with myeloma cells from 28 patients. Successful engraftment of unseparated BM cells from 85% of patients and CD138-selected myeloma plasma cells from 81% of patients led to the production of patients’ M-protein isotypes and typical myeloma manifestations (osteolytic bone lesions and angiogenesis of rabbit origin). Myeloma cells grew exclusively in the rabbit bone, but were able to metastasize into another bone at a remote site in the same mouse. Cells from patients with extramedullary disease also grew along the outer surface of the rabbit bones. This demonstrates the ability of SCID-rab model, marked by a nonmyelomatous, nonhuman, and nonfetal microenvironment, to support the growth of CD138-expressing myeloma cells. This system can now be widely used to study the biology of myeloma and its manifestations and to develop novel therapeutic approaches for this disease.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  1. Anderson PN, Potter M . Induction of plasma cell tumours in BALB-c mice with 2,6,10,14-tetramethylpentadecane (pristane). Nature 1969; 222: 994–995.

    Article  CAS  Google Scholar 

  2. Potter M, Wax JS . Peritoneal plasmacytomagenesis in mice: comparison of different pristane dose regimens. J Natl Cancer Inst 1983; 71: 391–395.

    CAS  PubMed  Google Scholar 

  3. Radl J, Hollander CF, van den BP, de Glopper E . Idiopathic paraproteinaemia. I. Studies in an animal model – the ageing C57BL/KaLwRij mouse. Clin Exp Immunol 1978; 33: 395–402.

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Asosingh K, Radl J, Van RI, Van Camp B, Vanderkerken K . The 5TMM series: a useful in vivo mouse model of human multiple myeloma. Hematol J 2000; 1: 351–356.

    Article  CAS  Google Scholar 

  5. Pilarski LM, Hipperson G, Seeberger K, Pruski E, Coupland RW, Belch AR . Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice. Blood 2000; 95: 1056–1065.

    CAS  PubMed  Google Scholar 

  6. Reiman T, Seeberger K, Taylor BJ, Szczepek AJ, Hanson J, Mant MJ et al. Persistent preswitch clonotypic myeloma cells correlate with decreased survival: evidence for isotype switching within the myeloma clone. Blood 2001; 98: 2791–2799.

    Article  CAS  Google Scholar 

  7. Pilarski LM, Belch AR . Clonotypic myeloma cells able to xenograft myeloma to nonobese diabetic severe combined immunodeficient mice copurify with CD34 (+) hematopoietic progenitors. Clin Cancer Res 2002; 8: 3198–3204.

    PubMed  Google Scholar 

  8. Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y et al. Characterization of clonogenic multiple myeloma cells. Blood 2004; 103: 2332–2336.

    Article  CAS  Google Scholar 

  9. Namikawa R, Ueda R, Kyoizumi S . Growth of human myeloid leukemias in the human marrow environment of SCID-hu mice. Blood 1993; 82: 2526–2536.

    CAS  PubMed  Google Scholar 

  10. Urashima M, Chen BP, Chen S, Pinkus GS, Bronson RT, Dedera DA et al. The development of a model for the homing of multiple myeloma cells to human bone marrow. Blood 1997; 90: 754–765.

    CAS  PubMed  Google Scholar 

  11. Yaccoby S, Barlogie B, Epstein J . Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood 1998; 92: 2908–2913.

    CAS  PubMed  Google Scholar 

  12. Yaccoby S, Epstein J . The proliferative potential of myeloma plasma cells manifest in the SCID-hu host. Blood 1999; 94: 3576–3582.

    CAS  PubMed  Google Scholar 

  13. Pearse RN, Sordillo EM, Yaccoby S, Wong BR, Liau DF, Colman N et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci USA 2001; 98: 11581–11586.

    Article  CAS  Google Scholar 

  14. Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y, Epstein J . Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 2002; 116: 278–290.

    Article  Google Scholar 

  15. Yaccoby S, Johnson CL, Mahaffey SC, Wezeman MJ, Barlogie B, Epstein J . Antimyeloma efficacy of thalidomide in the SCID-hu model. Blood 2002; 100: 4162–4168.

    Article  CAS  Google Scholar 

  16. Graur D, Duret L, Gouy M . Phylogenetic position of the order Lagomorpha (rabbits, hares and allies). Nature 1996; 379: 333–335.

    Article  CAS  Google Scholar 

  17. Miyashita EM, Yang B, Lam KM, Crawford DH, Thorley-Lawson DA . A novel form of Epstein–Barr virus latency in normal B cells in vivo. Cell 1995; 80: 593–601.

    Article  CAS  Google Scholar 

  18. Asosingh K, De Raeve H, Croucher P, Goes E, Van RI, Van Camp B et al. In vivo homing and differentiation characteristics of mature (CD45−) and immature (CD45+) 5T multiple myeloma cells. Exp Hematol 2001; 29: 77–84.

    Article  CAS  Google Scholar 

  19. Asosingh K, De Raeve H, Van RI, Van Camp B, Vanderkerken K . Multiple myeloma tumor progression in the 5T2MM murine model is a multistage and dynamic process of differentiation, proliferation, invasion, and apoptosis. Blood 2003; 101: 3136–3141.

    Article  CAS  Google Scholar 

  20. Croucher PI, Shipman CM, Lippitt J, Perry M, Asosingh K, Hijzen A et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 2001; 98: 3534–3540.

    Article  CAS  Google Scholar 

  21. Vanderkerken K, De Leenheer E, Shipman C, Asosingh K, Willems A, Van Camp B et al. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res 2003; 63: 287–289.

    CAS  Google Scholar 

  22. Van Valckenborgh E, De Raeve H, Devy L, Blacher S, Munaut C, Noel A et al. Murine 5T multiple myeloma cells induce angiogenesis in vitro and in vivo. Br J Cancer 2002; 86: 796–802.

    Article  CAS  Google Scholar 

  23. Bataille R, Chappard D, Marcelli C, Dessauw P, Baldet P, Sany J et al. Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest 1991; 88: 62–66.

    Article  CAS  Google Scholar 

  24. Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994; 87: 503–508.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by grants from the National Cancer Institute (CA-93897) and the Tobacco Settlement (SY). We thank the faculty and staff of the Myeloma Institute for Research and Therapy for their support and dedication to excellence in research and patient care. We also thank the University of Arkansas for Medical Sciences Office of Grants and Scientific Publications for editorial assistance during the preparation of this manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to S Yaccoby.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yata, K., Yaccoby, S. The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells. Leukemia 18, 1891–1897 (2004). https://doi.org/10.1038/sj.leu.2403513

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403513

Keywords

This article is cited by

Search

Quick links